SCHEMBL2769983

SCHEMBL2769983

O=C1c2ccccc2C(=O)c2cc(O)c(O)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 6/20 1.00
MCL1 Q07820 6/20 1.00
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
CDC25B P30305 1/20 0.63
PKLR P30613 1/20 0.62
APAF1 O14727 2/20 0.59
TDP2 O95551 2/20 0.59
MAOA P21397 5/20 0.58
MAPT P10636 4/20 0.58
MAOB P27338 2/20 0.54
ESR1 P03372 1/20 0.54
UGT1A1 P22309 1/20 0.54
ESR2 Q92731 1/20 0.54
MAPK1 P28482 4/20 0.54
ALDH1A1 P00352 3/20 0.54
CYP3A4 P08684 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
NPC1 O15118 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7979992 0.95 BCL2 (0.91) BCL2MCL1MEN1KMT2ACDC25B
SCHEMBL8821657 0.86 BCL2 (0.74) BCL2MCL1MEN1KMT2APKLR
SCHEMBL395884 0.84 MCL1 (0.72) BCL2MCL1MEN1KMT2ACDC25B
SCHEMBL27428387 0.84 BCL2 (0.72) BCL2MCL1MEN1KMT2ACDC25B
SCHEMBL11359105 0.84 BCL2 (0.72) BCL2MCL1MEN1KMT2ACDC25B
SCHEMBL6051235 0.84 BCL2 (0.72) BCL2MCL1MEN1KMT2ACDC25B
SCHEMBL7980260 0.83 BCL2 (0.70) BCL2MCL1MEN1KMT2APKLR
Anthraquinone SCHEMBL28260408 0.83 MEN1 (0.92) BCL2MCL1MEN1KMT2ACDC25B
SCHEMBL11072946 0.81 BCL2 (0.67) BCL2MCL1MEN1KMT2ACDC25B
SCHEMBL6629644 0.81 BCL2 (0.67) BCL2MCL1MEN1KMT2ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP claimed
CN-116598606-A Application of aromatic micromolecular electrolyte additive 中山大学 2023-08-15 CN claimed
US-9340643-B2 Alizarin-based polymer colorants XEROX CORPORATION (US) 2016-05-17 US claimed
US-20160017090-A1 Alizarin-Based Polymer Colorants XEROX CORPORATION 2016-01-21 US claimed
US-9181389-B2 Alizarin-based polymer colorants XEROX CORPORATION (US) 2015-11-10 US claimed
EP-2859068-A1 METHODS FOR SUPPRESSING DEHYDROGENATION Elevance Renewable Sciences, Inc. (US) 2015-04-15 EP claimed
US-20140342280-A1 Alizarin-Based Polymer Colorants XEROX CORPORATION (US) 2014-11-20 US claimed
WO-2013188200-A1 METHODS FOR SUPPRESSING DEHYDROGENATION ELEVANCE RENEWABLE SCIENCES, INC. (US) 2013-12-19 WO claimed
WO-2013188201-A1 METHODS OF REFINING NATURAL OILS, AND METHODS OF PRODUCING FUEL COMPOSITIONS ELEVANCE RENEWABLE SCIENCES, INC. (US) 2013-12-19 WO claimed
US-20130331586-A1 METHODS OF REFINING NATURAL OILS, AND METHODS OF PRODUCING FUEL COMPOSITIONS ELEVANCE RENEWABLE SCIENCES, INC. 2013-12-12 US claimed
US-20130331630-A1 METHODS FOR SUPPRESSING DEHYDROGENATION ELEVANCE RENEWABLE SCIENCES, INC. 2013-12-12 US claimed
EP-4700821-A1 TREATMENT SOLUTION AND METHOD FOR TREATING OBJECT TO BE TREATED FUJIFILM Corporation (JP) 2026-02-25 EP disclosed
US-20260028558-A1 TREATMENT LIQUID AND METHOD FOR TREATING OBJECT TO BE TREATED FUJIFILM CORP (JP) 2026-01-29 US disclosed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
CN-107847466-B Formulations and methods for modulating wound healing 贝欧曼蒂克丝公司 2024-02-06 CN disclosed
WO-1988004694-A1 DIGITAL THRESHOLD COLOR CONTROL SYSTEM ENZYMATICS, INC. (US) 1988-06-30 WO disclosed
EP-0147639-B1 STABILIZED SOLUTIONS OF HYDROXYL AMINE OR SALTS THEREOF BASF Aktiengesellschaft (DE) 1987-07-22 EP disclosed
US-4576804-A HYDROXYANTHRAQUINONES BASF AKTIENGESELLSCHAFT (DE) 1986-03-18 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed
US-4299946-A THERMOSETTING RESINS RHONE-POULENC INDUSTRIES (FR) 1981-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028558-A1 TREATMENT LIQUID AND METHOD FOR TREATING OBJECT TO BE TREATED AOC1, EPCAM, AOC2 BCL2 376/4885MCL1 459/4885MEN1 4569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.